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Introduction: The standard treatment concept in patients with locally advanced adenocarcinoma of the
esophagogastric junction is neoadjuvant chemotherapy, followed by tumor resection in curative intent.
Response evaluation of neoadjuvant chemotherapy using histopathological tumor regression grade (TRG)
has been shown to be a prognostic factor in patients with esophageal cancer. Methods: We assessed the
impact of the various methods of response control and their value in correlation to established prog-
nostic factors in a cohort of patients with adenocarcinoma at the gastroesophageal junction treated by
neoadjuvant chemotherapy. Results: After neoadjuvant chemotherapy, in 56 consecutive patients with
locally advanced (T2/3/4 and/or N0/N1) esophageal adenocarcinoma an oncologic tumor resection for
curative intent was performed. Median follow-up was 44 months. Histopathological tumor stages were
stage 0 in 10.7%, stage I in 17.9%, stage II in 21.4%, stage III in 41.1% and stage IV 8.9%. The 3-year overall
survival (OS) rate was 30.3%. In univariate analysis, ypN-status, histopathological tumor stage and tumor
regression grade correlated signiﬁcantly with overall survival (p ¼ 0.022, p ¼ 0.001, p ¼ 0.035 respec-
tively). Clinical response evaluation could not predict response and overall survival (p ¼ 0.556, p ¼ 0.254
respectively). Conclusion: After preoperative chemotherapy, outcomes of esophageal carcinoma are best
predicted utilizing pathological tumor stage and histologic tumor regression. Clinical response assess-
ments were not useful for guidance of treatment.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The incidence of the adenocarcinoma of the esophagogastric
junction (AEG) is growing rapidly in Western countries [1]. At
diagnosis, the majority of patients have locally advanced disease
with tumor penetration into the muscular wall or lymph node
metastases with consecutive poor 5-year survival rate of 30% [2e4].gen.de (R. Bachmann).
by Elsevier Ltd. All rights reservedAEG is divided into three subtypes: type I, adenocarcinoma of
the distal esophagus with the center located within 1 cm above and
5 cm above the anatomic esophagogastric junction (EGJ); type II,
carcinoma of the cardia with the tumor center within 1 cm above
and 2 cm below the EGJ; type III, subcardial carcinoma with the
tumor center between 2 cm and 5 cm below EGJ, which inﬁltrates
the EGJ and distal esophagus from below [5].
Treatment is performed stage dependent, in locally advanced
stages usually in a multimodality treatment concept. Hereby, sur-
gical resection remains the basis of cure: Beside R0-resection,
additional factors are favoring the outcome especially a complete.
Table 1
Shows the characteristics of 56 patients with adenocarcinoma of the esophagus.
Parameter No. (%) of patients
Median age (lower/upper quartile) 61 (54/71)
Gender
Male 51 (91.1)
female 5 (8.9)
Localization
AEG I 20 (35.7)
AEG II 21 (37.5)
AEG III 15 (26.8)
cT category
cT2 10 (17.9)
cT3 43 (76.8)
cT4 3 (5.4)
cN category
cN0 13 (23.2)
cNþ 43 (76.8)
Grading (bei ED)
G1 1 (1.8)
G2 30 (53.6)
G3 25 (44.6)
pT category
yp stage 0 6 (10.7)
yp stage I 10 (17.9)
yp stage II 12 (21.4)
yp stage III 23 (41.1)
yp stage IV 5 (8.9)
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by improved ﬁve-year survival [6]. For early identiﬁcation of non-
response to neoadjuvant chemotherapy next to computed tomog-
raphy (CT), esophagogastroscopy and endoscopic ultrasound (EUS)
the additional response evaluation with [18F] FDGePETeCT has
been introduced to identify patients without beneﬁt from multi-
modality therapy. In this regard, recent studies showed contradic-
tionary results using PETeCT for response evaluation [7,8].
Therefore, we retrospectively evaluated the efﬁcacy of the
neoadjuvant chemotherapy aiming to explore the value of
morphologic tumor regression in prediction of histopathologic
response, overall (OS)- and disease-free (DFS) survival after neo-
adjuvant chemotherapy for locally advanced carcinoma of the
esophagogastric junction.
2. Materials and methods
2.1. Patients
Criteria for inclusion in this study were the following: (1) uni-
focal adenocarcinoma of the esophagogastric junction; (2) tumors
without metastasis and either with or without lymph node
involvement on CT scan (cT3e4, cN0, M0 or cT1e4, cN1, M0); (3)
tumors deemed to be resectable as a curative attempt and (4)
performed neoadjuvant chemotherapy. Between 2006 and 2011, 56
consecutive patients met the inclusion criteria and their medical
charts were reviewed. All included patients underwent surgery
with curative intent after neoadjuvant chemotherapy for locally
advanced disease at the Division of General and Visceral Surgery at
the University hospital Tübingen.
2.2. Staging
According to the national guidelines, resectability was deter-
mined through thoracoabdominal computed tomography scans
and esophageal endoscopic ultrasonography (EUS). The tumor size
in the computed tomography scans was documented before and
after chemotherapy as well as the size of enlarged peritumoral
lymph nodes.
2.3. Classiﬁcation
For tumor classiﬁcation the known deﬁnition of Siewert et al.
was used [9,10]. Using this classiﬁcation there were 20 patients
with an AEG I, 21 patients with an AEG II and 15 with a tumor
classiﬁcation AEG III.
2.4. Chemotherapy
Patients were treated with neoadjuvant chemotherapy
with 35 patients receiving 5-ﬂuorouracil/leucovor-
ineoxaliplatinedocetaxel (FLOT), 10 patients receiving
Cisplatine5-FUeleucovorin (PLF), 3 patients receiving
Oxaliplatineleucovorine5-FU (FOLFOX), 3 patients receiving epi-
rubicineoxaliplatinecabecitabine (EOX), 3 patients receiving epi-
rubicinecisplatineﬂuorouracil (ECF), and 2 patients receiving a
docetaxelecisplatineﬂuorouracil (DCF) combination. In the post-
operative setting all patients got adjuvant chemotherapy.
2.5. Surgical treatment
If the majority of tumor was in the distal esophagus (Siewert I/
II), the operation was carried out as a two-phase abdominal and
right chest approach for enbloc subtotal esophagectomy followed
by a double-stapled esophagogastric anastomosis. Extended D1resection with dissection of the celiac nodes was performed. If the
majority of tumor was in the stomach (Siewerts type III), a gas-
trectomywas performed alongwith the esophagectomy through an
abdominal incision. The proximal jejune intestine was used as
conduit and anastomosed side-to-end to the remaining esophagus.
The distal anastomosis was done as a Roux-en-y reconstruction.
2.6. Image analysis according to RECIST
Unidimensional measurements of the long axis of tumors on
coronal CT images were performed using a caliper on the monitor,
with reference tomultiplanar reconstruction images (axial, coronal,
and sagittal imaging) and enhanced CT images. Objective thera-
peutic responses according to RECIST 1.1 [11] were as follows:
complete response (CR) was disappearance of tumor foci for at least
4 wk; partial response (PR) was a decline of at least 30% in tumor
diameter for at least 4 wk; stable disease was neither PR nor pro-
gressive disease (PD); and PD was at least a 20% increase in tumor
diameter for at least 4 wk.
2.7. Histomorphologic staging and grading of tumor regression
Two independent pathologists from the Department of Pathol-
ogy at the University of Tübingen conﬁrmed the histological diag-
nosis of the resected tissue. The results were classiﬁed according to
the TNM-classiﬁcation, including the grade of regression as
described before [12]: Complete tumor regression (regression
grade 1a); marked regression (less than 10% viable tumor, regres-
sion grade Ib); regression to 10e50% remaining viable tumor
(regression grade II) and bad regression (more than 50% viable
tumor remaining, regression grade III).
2.8. Statistical analysis
Statistical analysis was done using SPSS software, version 21
(SPSS Inc., Chicago, IL, USA). Results are reported as median and
lower and upper quartiles. Survival curves were calculated using
KaplaneMeier analysis and the log rank test. For testing signiﬁcant
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ManneWhitney U test was used. A signiﬁcance level <0.05 was
deﬁned.
3. Results
3.1. Study population
Between January 2006 and April 2011 ﬁfty-six patients with an
esophageal adenocarcinoma underwent tumor resection with
curative intent after a preoperative chemotherapy, 51 males (91%)
and 5 females (9%). Median age was 61 years. In 20 patients we
found AEG I, in 21 patients AEG II and in 15 patients AEG III. Initial
clinical tumor staging showed 10 patients with cT2, 43 patients
with cT3 and 3 patients with cT4. Nodalpositivity (cNþ) was seen in
43 patients (76.8%). In the postoperative tumor staging, 6 patients
showed yp-stage 0, 10 patients showed yp-stage I, 12 patients
showed yp-stage II, 23 patients showed yp-stage III and 5 patients
showed yp-stage IV. Table 1 shows the patients' characteristics in
detail.
3.2. Surgical results
In 44 patients an abdomino-thoracic subtotal esophagectomy
with an esophagojejunostomy to restore gastrointestinal continuity
and lymphadenectomy was performed; in 12 patients a transhiatal
extended total gastrectomy was done, including a radical lymph
node resection followed by an esophagojejunostomy. 47 patients
(83.9%) showed R0-resection, 8 patients (14.3%) showed micro-
scopical residual tumor (R1-resection) and 1 patient had macro-
scopical residual tumor (R2-resection). There was no perioperative
death documented (Table 2).
3.3. Treatment response assessments
3.3.1. Downstaging of tumor and lymph nodes
In the ypT-category complete tumor response was seen in 6
patients (10.7%), ypT1 in 3 patients (5.4%), ypT2 in 19 patients
(34%), ypT3 in 26 patients (46.4%) and ypT4 in 2 patients (3.6%). In
the ypN-category nodalpositivity was seen in 32 patients (57.1%)
and nodalnegativity in 24 patients (42.9%). Histomorphologic tu-
mor regression grading showed major response (Becker I) in 13Table 2
Shows the surgical treatment and the response to treatment.
Parameter No. (%)of patients
Operation:
- Abdomino-thoracic esophagectomy 44 (78.9)
- Transhiatal extended total gastrectomy 12 (21.1)
Resection
R0 47 (83.9)
R1 8 (14.3)
R2 1 (1.8)
ypT category
ypT0 6 (10.7)
ypT1 3 (5.4)
ypT2 19 (34)
ypT3 26 (46.4)
ypT4 2 (3.6)
ypN category
ypN0 24 (42.9)
ypNþ 32 (57.1)
Classiﬁcation of histomorphologic tumor regression
I (1a/b) 13 (23.2)
II 7 (12.5)
III 36 (64.3)patients (23.2%), intermediate response (Becker II) in 7 patients
(12.5%) and non-response (Becker III) in 36 patients (64.3%)
(Table 2).
3.3.2. Histological
With 8 patients (40%) from AEG I, 4 patients (19%) from AEG II
and 1 patient (6.7%) from AEG III showing major histopathological
response, tumor localization did not affect histological outcome
(Table 3).
3.3.3. CT and PETeCT (Table 4)
Used stagingmodalities for responsemonitoring of neoadjuvant
chemotherapy were heterogenous: In 18 patients PETeCT was
used, in 54 patients CT-scan was performed. In CT-staging and re-
staging after neoadjuvant chemotherapy tumor partial response
was seen in 35 (64.8%) patients, no change was seen in 16 (29.6%)
patients and progression of disease was seen in 3 (5.6%) patients;
regarding lymph node status, partial response was seen in 31
(57.4%) patients, no change in 20 (37.0%) patients and progression
of disease was seen in 3 (5.6%) patients. In PET/CT-staging and re-
staging after neoadjuvant chemotherapy tumor response was
seen in 12 (66.67%) patients, no change was seen in 3 (16.67%)
patients and progression of disease was seen in 3 (16.67%) patients;
regarding lymph node, response was seen in 9 (50.0%) patients, no
change in 8 (44.4%) patients and progression of disease was seen in
1 (5.56%) patient. Imaging modalities taken together showed in 38
patients (67.9%) partial response, in 8 patients (14.3%) no change
and progression of disease in 8 patients (14.3%).
The imaging modalities showed no clearly predictable response
in comparison to the ﬁnal histological results (p ¼ 0.556) (Table 4).
3.4. Survival and relapse patterns
During the study period, 26 (46.4%) patients died. 31 (55.4%)
patients experienced recurrence. The overall median survival was
44 month with 3-years survival rates of 30.3% (N ¼ 15) (Fig. 1).
Univariate analysis of survival showed no statistical inﬂuence of
clinical tumor (cT) or lymph node (cN) status (p ¼ 0.810, p ¼ 0.114).
The pathological tumor (ypT) status after neoadjuvant chemo-
therapy showed as well no statistically relevant inﬂuence with a
clear trend to improved survival the lower the tumor status
(p ¼ 0.077). Resection status (R-category) (p ¼ 0.001), grade of
histomorphologic tumor regression (p ¼ 0.035) (Figs. 3 and 4),
pathological lymph node (ypN) status (p ¼ 0.022) and pathological
stage (UICC) (p ¼ 0.001) (Fig. 2) had signiﬁcant inﬂuence on sur-
vival (Table 5).
The prevalence of tumor recurrence was clearly predictable
classifying into major (grade Ia/b) and minor histomorphologic (II,
III) regression (p ¼ 0.004). The regression grade has a signiﬁcant
inﬂuence on the incidence of tumor recurrence after tumor resec-
tion (Table 6).
4. Discussion
The presented study shows the methods of staging, the evalu-
ation of histopathological response and the outcome of patientsTable 3
Shows the tumor localization in correlation to the histopathological therapy
response.
Tumor type Becker 1a/b N (%) Becker 2/3 N (%)
AEG I 8 (40) 12 (60)
AEG II 4 (19) 17 (81)
AEG III 1 (6.7) 14 (93.3)
Table 4
Shows the apparative response evaluation in correlation to the histomorphological
response evaluation.
Parameter N (%) p-value
CT-scan T PR 35 (64.8) 0.616
NC 16 (29.6)
PD 3 (5.6)
N PR 31 (57.4) 0.533
NC 20 (37.0)
PD 3 (5.6)
PETeCT T PR 12 (66.67) 0.442
NC 3 (16.67)
PD 3 (16.67)
N PR 9 (50) 0.613
NC 8 (44.4)
PD 1 (5.6)
CT-scan and/or PETeCT T and/or N PR 38 (70.4) 0.556
NC 8 (14.8)
PD 8 (14.8)
Fig. 1. Shows the overall survival of all patients (n ¼ 56). The overall median survival
was 44 month with 3-years survival rates of 30.3% (N ¼ 15).
Fig. 2. Shows the survival in correlation to the pathological tumor stage UICC.
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noma at the gastroesophageal junction and delivers three main
results: Firstly, clinical response evaluation is not highly associated
with pathological response. Secondly, in addition to radical resec-
tion, histopathological response and nodalnegativity in the histo-
logical workup were indicators of improved survival. Finally, the
analyzation of histopathological tumor response in comparison to
outcome showed two main streams with better outcome in pa-
tients with ‘major tumor regression’ and worse outcome in patients
with ‘minor tumor regression’.
The limited number of patients has to be acknowledged.
Furthermore, the accuracy of PETeCT-evaluation is limited due to
the small number of patients out of this subgroup.
The main step in the multimodal treatment concept for cure of
adenocarcinoma at the esophagogastric junction remains surgical
resection with lymph node dissection. Transhiatal or combined
thoracoabdominal esophagectomy is traditionally regarded as
standard treatment for patients with locally advanced esophageal
cancer in combination with neoadjuvant chemotherapy [13]. For
further improvement of survival in multimodality treatment
approach, the introduction of early response evaluation using
PETeCT was introduced. The feasibility of [18F] FDGePETeCT in
predicting response to neoadjuvant chemotherapy in esophageal
adenocarcinoma, was presented in the MUNICON II trial by Lordick
et al. [14]. They showed that regression of tumor FDG metabolism
during neoadjuvant chemotherapy could serve to guide patients
into either a neoadjuvant and surgery-, or a surgery-only group.
Otherwise, the German Advanced Surgical Treatment Study
Group stated that there is currently no universally accepted,
reproducible, and reliable method for response assessment after
neoadjuvant treatment of esophageal carcinoma. This is due in part
to differing neoadjuvant therapy regimens, differing methods for
response assessment, e.g., CT scan, endoscopy, endoscopic ultra-
sound or PETeCT, and differing time frames for response control,
which leads to varying deﬁnitions of “response” and “non-
response” [15].
This is a retrospective single institution analysis of 56 consec-
utive patients with locally advanced esophageal carcinoma treated
with neoadjuvant chemotherapy. In this retrospective evaluation,
we investigated the outcome of patients with adenocarcinoma at
the gastroesophageal junction and the impact of response evalua-
tion after neoadjuvant chemotherapy followed by surgicalFig. 3. Shows the survival in correlation to the histopathological tumor regression.
Fig. 4. Shows the survival in correlation to major (Ia/b) and minor (II, III) histopath-
ological tumor regression.
Table 6
Shows the major and minor histomorphological response and prevalence of tumor
recurrence.
Grade of regression No tumor recurrence N [%] Tumor recurrence N [%] P value
I a/b 14 (73.7) 5 (26.3) 0.004
II and III 12 (32.4) 25 (67.6)
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advanced esophageal carcinoma, we reviewed several clinical and
histological parameters. There are different staging modalities and
methods of response evaluation: The combination of CT, endoscopyTable 5
Shows the univariate cox regression analysis of survival in month.
Parameter No.(%) of
patients
Median survival
(month)
p-
value
Clinical T status 0.810
cT1-2 e e
cT2 10 (17.9) 44
cT3 43 (76.8) 33
cT4 3 (5.4) 37
Clinical N status 0.114
cN0 13 (23.2) 44
cNþ 43 (76.8) 33
Classiﬁcation of histomorphologic
tumor regression
0.035
Ia/b 13 (23.2) 43 (Mean
survival)
II 7 (12.5) 44
III 35 (64.3) 26
ypT-category
ypT0 6 (10.7) e
ypT1 3 (5.4) e 0.077
ypT2 19 (34) 26
ypT3 26 (46.4) 33
ypT4 2 (3.6) 23
ypN category
ypN0 24 (42.9) 42 (Mean
survival)
0.022
ypNþ 31 (57.1) 23
Pathological stage (UICC)
ypStage 0 6 (10.7) e 0.001
ypStage I 10 (17.9) 44
ypStage II 12 (21.4) 36
ypStage III 23 (41.1) 26
ypStage IV 5 (8.9) 3
R category
R0 46 (83.9) 44 0.000
R1 8 (14.3) 6
R2 1 (1.8) e
R category, residual tumor category according to UICC; grade Ia complete response
(pCR, ypT0); grade Ib) nearly complete response (NCR) with 10% VRTCs, grade II:
10%e50% VRTCs (partial response), grade III 50% vital residual tumor cells (VRTCs).
ypT/ypN, histopathologic tumor/lymph node categories following neoadjuvant
treatment according to UICC.and endoscopic ultrasound (EUS) for preoperative staging is
considered as best preoperative clinical work-up. More ambiguous
are the methods of consecutive response evaluation. Numerous
reports showed conﬂicting results with various studies showing
PET/CT-improved prediction possibility of response and survival
[16], and others without [8]. Regarding response evaluation, in our
study the histopathological effect could not be concluded by
radiological methods.
Main factors for survival in our study were surgical resection
status, histopathological regression grading and pathological tumor
stage. Complete remission in primary tumor and lymph nodes
(ypT0 ypN0) was the best possible pathological outcome of
chemotherapy. The observed percentage of patients with a patho-
logical complete response was 10.7%. The prevalence of tumor
recurrence was clearly predictable classifying into major (grade Ia/
b) andminor histomorphologic (II, III) regression (p¼ 0.004). Major
response was seen in 23.2% of patients. The rate of histopathologic
non-responder was 64%. In these patients the overall survival was
signiﬁcantly reduced.
In locally advanced esophageal carcinoma multimodality treat-
ment approach shows signiﬁcant better survival. As response to
preoperative treatment is the most important prognostic factor
future therapy should optimize preoperative treatment. Whether
esophagogastric-junction adenocarcinomas should be treated by
perioperative chemotherapy or preoperative chemoradiotherapy is
under debate. The actual treatment concept using perioperative
chemotherapy is based on the results of theMAGIC [6] and ACCORD
[17] trial. Contrary showed the POET trial including patients with
esophageal and esophagogastric-junction adenocarcinomas and
randomizing into preoperative chemotherapy or chemo-
radiotherapy [18]. In this study a clear trend towards survival
advantage for preoperative chemoradiotherapy compared with
preoperative chemotherapy was shown.
5. Conclusion
1) Clinical response evaluation is not highly associated with
pathological response and should not be used for clinical deci-
sion making on delaying/avoiding surgery.
2) Evaluation of histopathological tumor response should classify
all patients into ‘major tumor regression’ and ‘minor tumor
regression’.
3) In addition to radical resection, histopathological response and
nodalnegativity in the histological workup were indicators of
improved survival.Ethical approval
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